Stock GBSX MARIZYME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Marizyme, Inc.

Equities

GBSX

US5703721028

Market Closed - OTC Markets
Other stock markets
 03:03:30 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.095 USD 0.00% Intraday chart for Marizyme, Inc. +72.73% -5.09%
Feb. 06 Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors CI
2023 Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
GL
Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors
CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Marizyme CEO Delivers Business Update
EQ
Marizyme CEO Delivers Business Update
GL
OTC Active Stocks Watchlist (EPAZ, MRZM, GCEI, TMGI)
AQ
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
GL
Marizyme, Inc. Announces FDA Clearance for Product, Duragraft
CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
MARIZYME, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Marizyme, Inc. announced a financing transaction
CI
MARIZYME INC : Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
GL
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
AQ
Marizyme, Inc. Announces IP Developments for DuraGraft and its Pipeline of Products
CI
Marizyme, Inc. announced that it has received $0.265216 million in funding
CI
Marizyme CEO Delivers Business Update
GL
MARIZYME INC Submission of Matters to a Vote of Security Holders (form 8-K/A)
AQ
MARIZYME INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GBSX Stock
  4. News Marizyme, Inc.